-
1.发明授权
公开(公告)号：US4935404A
公开(公告)日：1990-06-19
申请号：US270085
申请日：1988-11-14
IPC分类号： A61K38/55 , A61K38/00 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07F9/30 , C07F9/38 , C07F9/40 , C07F9/572 , C07K5/06
CPC分类号： C07F9/4006 , C07K5/06191 , A61K38/00
摘要： Novel compounds of the formula (I), a process for their preparation and their use as collagenase inhibitors are described: ##STR1## in which R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen or alkyl; R.sub.3 is C.sub.3-6 alkyl; R.sub.4 is hydrogen, alkyl, --CH.sub.2 --Z where Z is optionally substituted phenyl or heteroaryl, or R.sub.4 is a group ##STR2## where R.sub.8 is hydrogen, alkyl or --CH.sub.2 --Ph where Ph is optionally substituted phenyl, and R.sub.9 is hydrogen or alkyl; and R.sub.5 is hydrogen or alkyl.
-
公开(公告)号：US5212163A
公开(公告)日：1993-05-18
申请号：US758356
申请日：1991-09-09
CPC分类号： C07F9/3808 , C07F9/4006 , C07F9/5532 , C07F9/5728 , C07K5/06191 , C07K5/0827
摘要： Novel compounds of formula (I) and salts, solvates and hydrates thereof, processes for their preparation and their use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs: ##STR1## in which, R is hydrogen, C.sub.1-6 alkyl or optionally substituted benzyl; R.sub.1 is hydrogen or C.sub.1-6 alkyl; R.sub.2 is C.sub.3-6 alkyl; R.sub.3 is hydrogen, alkyl, --CH.sub.2 --Z where Z is optionally substituted phenyl or heteroaryl, or R.sub.3 is a group ##STR2## where R.sub.7 is hydrogen, alkyl or --CH.sub.2 --Ph where Ph is optionally substituted phenyl and R.sub.8 is hydrogen or alkyl; and R.sub.4 is --CH.sub.2 --(CH.sub.2).sub.n OR.sub.5 or --CH.sub.2 --(CH.sub.2).sub.n OCOR.sub.6 or --CH(R.sub.9)COR.sub.10, where n is an integer from 1 to 6; R.sub.5, R.sub.6 and R.sub.9 are hydrogen or C.sub.1-6 alkyl; and R.sub.10 is hydroxy or --O--C.sub.1-6 alkyl or --NR.sub.5 R.sub.6 (where R.sub.5 and R.sub.6 may be linked to form a heterocyclic ring; or R.sub.3 and R.sub.4 are joined together as --(CH.sub.2).sub.m -- where m is an integer from 4 to 12.
摘要翻译： 式（I）的新型化合物及其盐，溶剂化物和水合物，其制备方法及其用于治疗结缔组织和身体其它蛋白质成分降解的病症发生：其中（I） ，R为氢，C 1-6烷基或任选取代的苄基; R1是氢或C1-6烷基; R2是C3-6烷基; R3是氢，烷基，-CH2-Z，其中Z是任选取代的苯基或杂芳基，或R3是基团，其中R7是氢，烷基或-CH2-Ph，其中Ph是任选取代的苯基，R8是氢或烷基 ; 并且R 4是-CH 2 - （CH 2）nOR 5或-CH 2 - （CH 2）nOCOR 6或-CH（R 9）COR 10，其中n是1至6的整数; R5，R6和R9是氢或C1-6烷基; 并且R 10是羟基或-O-C 1-6烷基或-NR 5 R 6（其中R 5和R 6可以连接形成杂环;或者R 3和R 4连接在一起作为 - （CH 2）m - ，其中m是4的整数 到12岁
-
公开(公告)号：US4837238A
公开(公告)日：1989-06-06
申请号：US112050
申请日：1987-10-21
申请人： Roger E. Markwell , Ian Hughes , Robert W. Ward
发明人： Roger E. Markwell , Ian Hughes , Robert W. Ward
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Compounds of the formula (I): ##STR1## wherein: X is NR wherein R is hydrogen, C.sub.1-6 alkyl; oxygen; sulphur; SO; or SO.sub.2 ; or R and R.sub.3 taken together are C.sub.4-6 polymethylene;R.sub.1 is hydrogen or C.sub.1-6 alkyl; and R.sub.2 is CN, CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or R.sub.8 and R.sub.9 together are C.sub.4-6 polymethylene, or COR.sub.10 where R.sub.10 is C.sub.1-4 alkyl, provided that Y is other than hydrogen when R.sub.1 is hydrogen;orR.sub.2 is hydrogen C.sub.1-6 alkyl or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above;orR.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl;R.sub.3 is C.sub.1-10 alkyl or C.sub.3-10 cycloalkyl, either optionally substituted by hydroxy, C.sub.1-4 alkoxy, thiol, C.sub.1-4 alkylthio or NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently hydrogen, C.sub.1-6 alkyl or C.sub.2-7 alkanoyl or together are C.sub.3-6 polymethylene; C.sub.2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.13 R.sub.14 wherein R.sub.13 and R.sub.14 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl, C.sub.1-6 alkylsulphonyl or COR.sub.15 wherein R.sub.15 is hydroxy, C.sub.1-6 alkoxy or NR.sub.16 R.sub.17 wherein R.sub.16 and R.sub.17 are independently selected from hydrogen or C.sub.1-6 alkyl; or together with R is C.sub.4-6 polymethylene; andR.sub.4 is hydrogen; or C.sub.1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl and is attached at nitrogen atom 1 or 2, are disclosed as having utility in the treatment of inflammatory and allergic disorders.
摘要翻译： 式（I）的化合物：其中：X是NR，其中R是氢，C 1-6烷基; 氧; 硫; 所以; 或SO2; 或R和R3一起为C4-6聚亚甲基; R1是氢或C1-6烷基; 并且R 2是CN，CR 5 R 6 Y，其中R 5和R 6独立地选自氢和C 1-4烷基，Y选自氢，OR 7或SR 7，其中R 7是氢，C 1-4烷基，C 2-4烷酰基和NR 8 R 9，其中R 8和 R 9独立地是氢，C 1-4烷基，C 2-4烯基或C 2-4烷酰基，或者R 8和R 9一起是C 4-6多亚甲基，或COR 10，其中R 10是C 1-4烷基，条件是Y不是氢，当R 1是 氢; 或R 2为氢或C 1-6烷基或任选被卤素，CF 3，C 1-4烷氧基或C 1-4烷基取代的苯基; 并且R 1是如上定义的CN，CR 5 R 6 Y或COR 10; 或R 1和R 2一起形成任选被C 1 -C 4烷基取代的C 3 -C 6聚亚甲基; R3是C1-10烷基或C3-10环烷基，任选被羟基，C 1-4烷氧基，硫醇，C 1-4烷硫基或NR 11 R 12取代，其中R 11和R 12独立地是氢，C 1-6烷基或C 2-7烷酰基或一起 是C3-6聚亚甲基; C 2-10烯基; 或任选被一个或两个卤素，CF 3，C 1-4烷氧基，C 1-4烷基，羟基，硝基，氰基，C 2-10酰氧基，NR 13 R 14取代的苯基，其中R 13和R 14独立地选自氢，C 1-6烷基， C 2-6烷酰基，C 1-6烷基磺酰基或COR 15，其中R 15是羟基，C 1-6烷氧基或NR 16 R 17，其中R 16和R 17独立地选自氢或C 1-6烷基; 或与R一起为C4-6聚亚甲基; R4为氢; 或在苯环中被卤素，CF 3，C 1-4烷氧基或C 1-4烷基中的一个或两个取代的C 1-4烷基或苄基，并且在氮原子1或2上连接，被公开用于治疗 炎性和过敏性疾病。
-
4.发明授权Pyrazolopyridine derivatives useful in treating inflammation and allergic conditions 失效可用于治疗炎症和过敏症状的吡唑并吡啶衍生物
公开(公告)号：US4670432A
公开(公告)日：1987-06-02
申请号：US852152
申请日：1986-04-15
申请人： Robert W. Ward , Roger E. Markwell
发明人： Robert W. Ward , Roger E. Markwell
IPC分类号： A61K31/435 , A61P29/00 , A61P37/08 , C07D231/16 , C07D231/38 , C07D471/04 , A61K31/44
CPC分类号： C07D231/38 , C07D231/16 , C07D471/04
摘要： A compound of formula (I) or a salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl;R.sub.2 is hydrogen or C.sub.1-6 alkyl;R.sub.3 is C.sub.2-10 alkenyl or C.sub.1-10 alkyl substituted by hydroxy, C.sub.1-4 alkoxy, thiol, C.sub.1-4 alkylthio or NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are independently hydrogen or C.sub.1-6 alkyl or together are C.sub.3-6 polymethylene;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-4 alkyl; andR.sub.6 is hydrogen; or C.sub.1-4 alkyl or benzyl attached at nitrogen atom 1 or 2;having anti-inflammatory and/or anti-allergy activity.
摘要翻译： 式（I）化合物或其盐：其中：R 1是氢，任选地被卤素，CF 3，C 1-4烷氧基或C 1-4烷基取代的C 1-6烷基或苯基; R2是氢或C1-6烷基; R3是C2-10烯基或被羟基，C1-4烷氧基，硫醇，C1-4烷硫基或NR7R8取代的C1-10烷基，其中R7和R8独立地是氢或C1-6烷基或一起是C3-6聚亚甲基; R4和R5独立地是氢或C1-4烷基; R6是氢; 或在氮原子1或2连接的C 1-4烷基或苄基; 具有抗炎和/或抗过敏活性。
-
公开(公告)号：US4833136A
公开(公告)日：1989-05-23
申请号：US8267
申请日：1987-01-29
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： A compound of the formula (I) or a salt or solvate thereof: ##STR1## in which: R.sub.0 is hydrogen or C.sub.1-6 alkyl; or together with R.sub.3 is C.sub.4-6 polymethylene;R.sub.1 and R.sub.2 are both hydrogen; orR.sub.1 is hydrogen, C.sub.1-6 alkyl; and R.sub.2 is CN; CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or together are C.sub.4-6 polymethylene; or COR.sub.10 where R.sub.10 is OH or C.sub.1-4 alkyl, or COR.sub.10 is a pharmaceutically acceptable ester or amide, orR.sub.2 is hydrogen, C.sub.1-6 alkyl, or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl, and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above; orR.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl;R.sub.3 is hydrogen; or C.sub.1-10 alkyl or C.sub.3-10 cycloalkyl, either optionally substituted by hydroxy, C.sub.1-4 alkoxy, thiol, C.sub.1-4 alkylthio or NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently hydrogen, C.sub.1-6 alkyl or C.sub.2-7 alkanoyl or together are C.sub.3-6 polymethylene; C.sub.2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.13 R.sub.14 wherein R.sub.13 and R.sub.14 are independently selected from hydrogen, C.sub.1-6 alkyl, or C.sub.2-7 alkanoyl; or COR.sub.15 wherein R.sub.15 is hydroxy, C.sub.1-6 alkoxy or NR.sub.16 R.sub.17 wherein R.sub.16 and R.sub.17 are independently selected from hydrogen or C.sub.1-6 alkyl; orR.sub.3 is a mono- or fused bi-cyclic heteroaryl group having up to ten atoms in the aromatic ring(s), not more than two of which are selected from nitrogen, oxygen or sulphur, other than those containing basic nitrogen, optionally substituted by one or two substituents selected from halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.23 R.sub.24 wherein R.sub.23 and R.sub.24 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl or C.sub.1-6 alkylsulphonyl; or COR.sub.25 wherein R.sub.25 is hydroxy, C.sub.1-6 alkoxy or NR.sub.26 R.sub.27 wherein R.sub.26 and R.sub.27 are independently selected from hydrogen or C.sub.1-6 alkyl;R.sub.4 is hydrogen, or C.sub.1-4 alkyl, phenyl or benzyl, each of which is optionally substituted in the phenyl ring by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl and is attached at nitrogen atom 1 or 2; andR.sub.x is C.sub.1-6 alkyl, halogen, nitro, NR.sub.18 R.sub.19 where R.sub.18 and R.sub.19 are independently hydrogen, C.sub.1-6 alkyl or C.sub.2-7 alkanoyl, nitrile, COOH, CONH.sub.2 ; phenyl or benzyl optionally substituted by one or two of halogen, nitro, C.sub.1-6 alkoxy, hydroxy, C.sub.2-7 alkanoyloxy, NR.sub.18 R.sub.19, C.sub.1-6 alkyl, CF.sub.3, CN; thienyl, furyl or pyrryl optinoally N-substituted by C.sub.1-6 alkyl,with the proviso that R.sub.0 and R.sub.3 are not both hydrogen when R.sub.1 is hydrogen and R.sub.2 and R.sub.x are methyl, is useful for treating inflammatory or allergic conditions.
-
6.发明授权Certain 7-amino-pyrazolo[4,3-b]pyridines useful in treating inflammatory and allergic disorders 失效某些7-氨基 - 吡唑并[4,3-b]吡啶可用于治疗炎性和过敏性疾病
公开(公告)号：US4716160A
公开(公告)日：1987-12-29
申请号：US856454
申请日：1986-04-25
IPC分类号： A61K31/44 , C07D471/04
CPC分类号： C07D471/04
摘要： Compounds of formula (I) ##STR1## wherein: R is hydrogen or C.sub.1-6 alkyl;R.sub.1 and R.sub.2 are both hydrogen; orR.sub.1 is hydrogen, C.sub.1-6 alkyl; and R.sub.2 is CN; CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or together are C.sub.4-6 polymethylene, or COR.sub.10 where R.sub.10 is OH or C.sub.1-4 alkyl, or COR.sub.10 is a pharmaceutically acceptable ester or amide; orR.sub.2 is hydrogen, C.sub.1-6 alkyl, or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above; orR.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl;R.sub.3 a mono- or fused bi-cyclic heteroaryl group having up to ten atoms in the aromatic ring(s), not more than two of which are selected from nitrogen, oxygen or sulphur, other than those containing basic nitrogen, optionally substituted by one or two substituents selected from halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl or C.sub.1-6 alkylsulphonyl; or COR.sub.13 wherein R.sub.13 is hydroxy, C.sub.1-6 alkoxy or NR.sub.14 R.sub.15 wherein R.sub.15 and R.sub.14 are independently selected from hydrogen or C.sub.1-6 alkyl; andR.sub.4 is hydrogen, or C.sub.1-4 alkyl, or benzyl optionally substituted in the phenyl ring by one or more of halogen, CF.sub.3, C.sub.1-4 alkyl, and is attached at nitrogen atom 1 or 2; show anti-inflammatory and anti-allergy activity.
摘要翻译： 式（I）化合物其中：R是氢或C 1-6烷基; R1和R2都是氢; 或R 1为氢，C 1-6烷基; R2为CN; CR5R6Y，其中R5和R6独立地选自氢和C1-4烷基，Y选自氢，OR7或SR7，其中R7是氢，C1-4烷基或C2-4烷酰基，和NR8R9，其中R8和R9独立地是氢， C 1-4烷基，C 2-4链烯基或C 2-4烷酰基或一起是C 4-6多亚甲基或COR 10，其中R 10是OH或C 1-4烷基，或COR 10是药学上可接受的酯或酰胺; 或R 2为氢，C 1-6烷基或任选被卤素，CF 3，C 1-4烷氧基或C 1-4烷基取代的苯基; 并且R 1是如上定义的CN，CR 5 R 6 Y或COR 10; 或R 1和R 2一起形成任选被C 1 -C 4烷基取代的C 3 -C 6聚亚甲基; R3是在芳环中具有至多10个原子的单或稠合双环杂芳基，其中不超过两个选自氮，氧或硫，除了含有碱性氮的那些，任选被一个 或选自卤素，CF 3，C 1-4烷氧基，C 1-4烷基，羟基，硝基，氰基，C 2-10酰氧基，NR 11 R 12中的两个取代基，其中R 11和R 12独立地选自氢，C 1-6烷基，C 2-7 烷酰基或C 1-6烷基磺酰基; 或COR 13，其中R 13是羟基，C 1-6烷氧基或NR 14 R 15，其中R 15和R 14独立地选自氢或C 1-6烷基; R 4是氢或C 1-4烷基，或在苯环中被一个或多个卤素，CF 3，C 1-4烷基取代的苄基，并且在氮原子1或2上连接; 显示抗炎和抗过敏活性。
-
公开(公告)号：US4818754A
公开(公告)日：1989-04-04
申请号：US39540
申请日：1987-04-16
申请人： Robert W. Ward , Roger E. Markwell , Ian Hughes
发明人： Robert W. Ward , Roger E. Markwell , Ian Hughes
IPC分类号： A61K31/435 , A61P29/00 , A61P37/08 , C07D471/04
CPC分类号： C07D471/04
摘要： A compound of the formula (1) or a salt or solvate thereof: ##STR1## in which: R.sub.0 is hydrogen or C.sub.1-6 alkyl;R.sub.1 and R.sub.2 are both hydrogen; orR.sub.1 is hydrogen, C.sub.1-6 alkyl; and R.sub.2 is CN; CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or together are C.sub.4-6 polymethylene; or COR.sub.10 is OH or C.sub.1-4 alkyl, or COR.sub.10 is a pharmaceutically acceptable ester or amide; orR.sub.2 is hydrogen, C.sub.1-6 alkyl, or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above; orR.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl;R.sub.3 is --(CH.sub.2).sub.n CO.sub.2 R.sub.11, --(CH.sub.2).sub.n CONR.sub.12 R.sub.13,--(CH.sub.2).sub.n CN, --(CH.sub.2).sub.m NHCOR.sub.14, ##STR2## where a, b, n, m and p are integers and n is 1 to 10, m is 2 to 10, p is 3 to 5, a is 1 to 3, and b is 1 to 3,and R.sub.11 is hydrogen, C.sub.1-8 alkyl, benzyl or phenyl, R.sub.12 and R.sub.13 are independently hydrogen, C.sub.1-6 alkyl, benzyl or phenyl, or together form C.sub.3-8 alkylene, R.sub.14 is C.sub.1-4 alkyl, benzyl or phenyl and X is oxygen, sulphur, NH or N--C.sub.1-4 alkyl, andR.sub.4 is hydrogen; or C.sub.1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl, and is attached at nitrogen atom 1 or 2, a process for its preparation and its use as a pharmaceutical.
摘要翻译： 式（1）的化合物或其盐或溶剂化物：其中：R 0是氢或C 1-6烷基; R1和R2都是氢; 或R 1为氢，C 1-6烷基; R2为CN; CR5R6Y，其中R5和R6独立地选自氢和C1-4烷基，Y选自氢，OR7或SR7，其中R7是氢，C1-4烷基或C2-4烷酰基，和NR8R9，其中R8和R9独立地是氢， C 1-4烷基，C 2-4烯基或C 2-4烷酰基或一起是C 4-6多亚甲基; 或COR 10是OH或C 1-4烷基，或COR 10是药学上可接受的酯或酰胺; 或R 2为氢，C 1-6烷基或任选被卤素，CF 3，C 1-4烷氧基或C 1-4烷基取代的苯基; 并且R 1是如上定义的CN，CR 5 R 6 Y或COR 10; 或R 1和R 2一起形成任选被C 1 -C 4烷基取代的C 3 -C 6聚亚甲基; R3是 - （CH2）nCO2R11， - （CH2）nCONR12R13， - （CH2）nCN， - （CH2）mNHCOR14，
其中a，b，n，m和p是整数，n是1到10 m为2至10，p为3至5，a为1至3，b为1至3，R 11为氢，C 1-8烷基，苄基或苯基，R 12和R 13独立地为氢，C 1-6 烷基，苄基或苯基，或一起形成C 3-8亚烷基，R 14是C 1-4烷基，苄基或苯基，X是氧，硫，NH或N-C 1-4烷基，R 4是氢; 或任选在苯环中被卤素，CF 3，C 1-4烷氧基或C 1-4烷基中的一个或两个取代的C 1-4烷基或苄基，并且在氮原子1或2上连接，其制备方法及其用途 作为药物。 -
8.发明授权
公开(公告)号：US4548948A
公开(公告)日：1985-10-22
申请号：US581440
申请日：1984-02-17
IPC分类号： A61K31/38 , C07C45/46 , C07C45/63 , C07C49/784 , C07C63/04 , C07D307/84 , C07D307/85 , C07D307/87 , C07D311/22 , C07D333/54 , C07D333/56 , C07D333/68 , C07D409/06 , C07F7/18 , A61K31/34 , A61K31/40 , C07D333/38
CPC分类号： C07D333/54 , C07C323/00 , C07C45/46 , C07C45/63 , C07C49/784 , C07C63/04 , C07D307/84 , C07D307/85 , C07D311/22 , C07D333/56 , C07D333/68 , C07D409/06 , C07F7/1852
摘要： Compounds of formula (I): ##STR1## wherein: Ar is phenyl optionally substituted in the o-, m- or p-position by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, bromo, chloro or fluoro,pyrryl optionally N-substituted by C.sub.1-4 alkyl,2-furyl or 2-thienyl either optionally substituted in the 3-, 4- or 5-position by methyl, chloro or bromo, or3-furyl or 3-thienyl;X is oxygen, sulphur, sulphoxide or sulphone, Y is methylene, R.sub.1 and R.sub.3 are hydrogen or C.sub.1-4 alkyl, and R.sub.2 is hydrogen, C.sub.1-4 alkyl, fluoro, chloro or bromo, or X is methylene, Y is oxygen, R.sub.1 and R.sub.3 are both hydrogen, and R.sub.2 is hydrogen, fluoro, chloro or bromo; andR.sub.4 is hydrogen or C.sub.1-4 alkyl, or a salt thereof, have analgesic and/or anti-inflammatory activity.
摘要翻译： 式（I）化合物：其中：Ar是任选地被C 1-4烷基，C 1-4烷氧基，三氟甲基，溴，氯或氟取代在邻位，间或对位的苯基， 任选被C1-4烷基，2-呋喃基或2-噻吩取代的吡咯基，其任选在3-，4-或5-位被甲基，氯或溴或3-呋喃基或3-噻吩基取代; X是氧，硫，亚砜或砜，Y是亚甲基，R 1和R 3是氢或C 1-4烷基，R 2是氢，C 1-4烷基，氟，氯或溴，或X是亚甲基，Y是氧， R1和R3都是氢，R2是氢，氟，氯或溴; R4为氢或C1-4烷基或其盐具有止痛和/或消炎活性。
-
9.发明授权Sensor assembly having embedded wires within a powder metal core and a method therefor 失效传感器组件在粉末金属芯内具有嵌入的线及其方法
公开(公告)号：US5315245A
公开(公告)日：1994-05-24
申请号：US983064
申请日：1992-11-25
CPC分类号： G01R33/09 , H01L43/02 , Y10T29/49007 , Y10T29/49076
摘要： A semiconductor magnetoresistive sensor and a method for its assembly is specifically provided. The preferred assembly method of this invention is compatible with automated semiconductor chip placement and packaging technology, so as to alleviate the previous requirement that the semiconductor sensing element be separately packaged. The sensor leads are substantially embedded within a powdered metal permanent magnet body. An exposed terminal end of each lead is available for electrical and adhesive contact to a subsequently attached magnetoresistive semiconductor sensing element, using conventional semiconductor placement and packaging techniques. The powdered metal magnetic body is preferably formed by utilizing powder metal compaction techniques, wherein the powder metal is compacted around the interior electrical leads. The teachings of this invention may also be employed to form a variety of electrical sensors and devices, wherein the leads are substantially embedded within a metal core so as to produce a solid assembly. The embedded leads may have a variety of shapes, such as straight or coiled, may range in number from one to a plurality, and may have a variety of physical properties, such as magnetic or non-magnetic, depending on the desired application.
摘要翻译： 具体地提供半导体磁阻传感器及其组装方法。 本发明的优选组装方法与自动半导体芯片放置和封装技术相兼容，以便减轻半导体传感元件分开封装的先前要求。 传感器引线基本上嵌入粉末状金属永磁体内。 使用常规的半导体放置和封装技术，每个引线的暴露端子可用于与随后附接的磁阻半导体感测元件的电和粘合接触。 粉末状金属磁体优选通过利用粉末金属压实技术形成，其中粉末金属在内部电引线周围压实。 本发明的教导也可用于形成各种电传感器和装置，其中引线基本上嵌入在金属芯内以便产生固体组件。 嵌入式引线可以具有各种形状，例如直线或卷绕，其数量可以在一个至多个的范围内，并且可以具有各种物理性质，例如磁性或非磁性，这取决于所需的应用。
-
公开(公告)号：US5175194A
公开(公告)日：1992-12-29
申请号：US881067
申请日：1992-05-11
IPC分类号： C09K21/02
CPC分类号： C09K21/02 , Y10S521/906
摘要： A flame retardant composition and process which is particularly useful for rebonded foam products. The composition of the present invention includes a solid component of magnesium sulfate, boric acid, decabromodiphenylethylene oxide (DECA) and antimony trioxide and a liquid component of halogenated phosphorous. The present invention is based upon the discovery of the synergism between boric acid and DECA. The process, according to the present invention, includes the steps of forming a dispersion of the solid portion of the flame retardant composition along with a small amount of water based adhesive to a mass of foam chips. The treated chips are then dried to permit handling and storage. The dried foam chips subsequently are mixed with a conventional urethane prepolymer binder and the liquid halogenated phosphorous flame retardant compound. After mixing the foam mass is transferred to molds and steamed to allow the binder to cure. Rebonded foam manufactured by this process displays excellent physical properties while, at the same time, exhibits a Flame Spread Index I.sub.s value of less than about 25.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.021 秒)
